ArticleFrontiers in oncology2023

Assessing real-world safety concerns of Sacituzumab govitecan: a disproportionality analysis using spontaneous reports in the FDA adverse event reporting system.

Xiujuan Gui et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.